Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 362 participants.

Also called NCT05293639

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 362 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05293639
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05293639. Allocation not applicable; no masking; primary purpose treatment. Start 2022-04-18 (actual); primary completion 2023-12-11 (actual). Results posted on 2025-04-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System
Acronym
AdmIRE
Intervention (Device)
Pulse Field Ablation
Lead sponsor
Biosense Webster, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05293639
Content hash
12b24ce8d979026c17b24f923a6d2c8ed53463829974009406b97f4442257fea